Oscar Health, Inc. (OSCR) Return on Equity (ROE): -2.37%
Is Oscar Health, Inc.’s return on equity (ROE) high or low?
Oscar Health, Inc.'s return on equity (ROE) of -2.37% is 91% above its 5-year average of -25.75%, around the middle of its 5-year range (-68.09%–31.39%).
As of Sunday, June 21, 2026. 88.93% above its 12-month average of -21.41%.
OSCR Return on Equity (ROE) Chart
OSCR Average Return on Equity (ROE) Chart
OSCR Current vs Average Return on Equity (ROE) Chart
OSCR Return on Equity (ROE) Metrics
RETURN ON EQUITY (ROE)
-2.37%
RETURN ON EQUITY (ROE) AVG TTM
-21.41%
RETURN ON EQUITY (ROE) AVG 3Y
-36.14%
RETURN ON EQUITY (ROE) AVG 5Y
-25.75%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+88.93%
CURRENT VS 3Y AVG
+93.44%
CURRENT VS 5Y AVG
+90.79%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
OSCR Competitors' Return on Equity (ROE)
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Oscar Health, Inc. (OSCR) | $7.36B | -2.37% | -21.41% | -36.14% | -25.75% |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $7.64B | 2.46% | -8.94% | -15.72% | 1.14% |
| Hims & Hers Health, Inc. (HIMS)vs › | $7.91B | -2.97% | 25.09% | 5.57% | 0.40% |
| Tempus AI, Inc. (TEM)vs › | $8.87B | -72.74% | -651.33% | -315.37% | -198.08% |
| Charles River Laboratories International, Inc. (CRL)vs › | $8.91B | -6.28% | -2.13% | 6.32% | 9.65% |
| Baxter International Inc. (BAX)vs › | $10.27B | -18.17% | -12.46% | -8.76% | -1.37% |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | -87.68% | -49.03% | -18.16% | -9.00% |
| Revvity, Inc. (RVTY)vs › | $11.16B | 3.35% | 3.59% | 3.35% | 7.68% |
| TransMedics Group, Inc. (TMDX)vs › | $2.72B | 34.80% | 27.86% | 4.54% | -12.45% |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $2.07B | -47.65% | -45.75% | -30.11% | -18.95% |
Return Analysis
ROE
-2.4%
ROA
-0.4%
Oscar Health, Inc. Return on Equity (ROE) Formula & Definition
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Oscar Health, Inc. Return on Equity (ROE) FAQ
- What is the return on equity (ROE) for Oscar Health, Inc. (OSCR)?
- The return on equity (ROE) for OSCR stock is -2.37%.
- Is Oscar Health, Inc.'s return on equity (ROE) high or low?
- Oscar Health, Inc.'s return on equity (ROE) of -2.37% is 91% above its 5-year average of -25.75%, around the middle of its 5-year range (-68.09%–31.39%).
- What is the TTM average return on equity (ROE) for Oscar Health, Inc. (OSCR)?
- The TTM average return on equity (ROE) for OSCR stock is -21.41%.
- What is the 3Y average return on equity (ROE) for Oscar Health, Inc. (OSCR)?
- The 3Y average return on equity (ROE) for OSCR stock is -36.14%.
- What is the 5Y average return on equity (ROE) for Oscar Health, Inc. (OSCR)?
- The 5Y average return on equity (ROE) for OSCR stock is -25.75%.
Oscar Health, Inc. Return on Equity (ROE) History
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | -45.33% |
| 2024-12-31 | 2.51% |
| 2023-12-31 | -33.67% |
| 2022-12-31 | -68.09% |
| 2021-12-31 | -41.28% |
| 2020-12-31 | 31.39% |
| 2019-12-31 | 27.63% |
Related Metrics
About Oscar Health, Inc.
Oscar Health, Inc. operates as a health insurance provider across the United States. Its offerings include various health plans such as those for individuals and families, small businesses, and Medicare Advantage options. The company also features "+Oscar," a proprietary technology platform designed to facilitate engagement between healthcare providers, payers, and their members or patients. Additionally, Oscar Health provides reinsurance solutions. Originally established as Mulberry Health Inc., the firm officially changed its name to Oscar Health, Inc. in January 2021. It was founded in 2012 and maintains its main office in New York, New York.
- Sector
- Healthcare
- Industry
- Medical - Healthcare Plans
- CEO
- Mark Thomas Bertolini